Peer Review, UGC Care
ANTIPSORIATIC ACTIVITY OF DITHRANOL TRANSDERMAL PRONIOSOMES GEL ON SWISS ALBINO MICE
View PDF

Keywords

Dithranol, Proniosomes, Psoriasis, Proniosomes Transdermal Gel.

How to Cite

Kumar, P. S., & Middha , A. (2014). ANTIPSORIATIC ACTIVITY OF DITHRANOL TRANSDERMAL PRONIOSOMES GEL ON SWISS ALBINO MICE. International Journal of Research and Development in Pharmacy & Life Sciences, 3(6), 1265-1273. Retrieved from https://ijrdpl.com/index.php/ijrdpl/article/view/404

Abstract

Psoriasis is distinguished by hyper-proliferation and unusual differentiation of epidermal keratinocytes, lymphocyte infilteration containing mainly of T lymphocytes. Psoriasis may be treated mainly by topical and dermal route because systemic therapy or phototherapy mainly concerns with the possible tissues toxicity and sometimes result in carcinogenicity. Beyond the various presently existing management options of psoriasis, topical therapy is the most widely used. Proniosomes create beneficial choice for transfer of the drug without delay. Simultaneously, its provided better physical and chemical stability than comparison to liposomes and niosomes. Proniosomes is converted to niosomes prior to action and release of drug. Proniosomal transdermal gel of Dithranol optimized preparation was used for antipsoriatic activity on Swiss albino mice give relevant result for treatment of psoriasis, without any tissue toxicity such as redness, erythema in animal skin, as well as convulsion, tremor, circling, depression, hypothermia and mortality. Percent drug activity of Proniosomal transdermal gel (1% w/w) was found to be 79.56% which show a significant antipsoriatic effect in comparison of standard drug Derobin® (1.125w/w) 82.31%. The frequently shown different side effects associated with dithranol, in this research solved related problem of existing preparation of dithranol by using of proniosomes transdermal gel preparation on animal body as tissue toxicity study.

View PDF

References

Kanitakis J. (2002) Anatomy, histology and immune histochemistry of normal human skin. Eur J Dermatol. 12(4): 390-399.

Basak SC, Vellaiyan K. (1997) Transdermal drug delivery system, Eastern Pharm. 40(1): 63-67.

Maya W, Ashar S. (2012) Proniosomal drug delivery systems: An overview, international journal of pharmaceutical and chemical sciences. 1 (3): 695-707.

Touitou E, Dayan N, Bergelson L, Godin B Eliaz M. (2000) Ethosomes- novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 65: 403-418.

Jain S, Jain P, Umamaheshwari RB, Jain NK. (2003) Transfersomes – a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind. Pharm. 29(9): 1013–1026.

Gordon K B, Ruderman EM. (2006) The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach, J. Am. Acad. Dermatol. 54: S86–S91.

Racz E, Prens EP, (2009) Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev. Mol. Med. 11: 38.

Clark AR, (2000) Topical noncorticosteroid therapies for psoriasis, Curr. Probl. Dermatol. 12: 230–232.

Saraceno R, Schipani C, Mazzotta A, Espositoa M, Renzo LD, Lorenzob AD, Henseler T, Christophers E, (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 13: 450-456.

Henseler T, Christophers E. (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 13: 450–456.

Menter A, Griffiths CE., (2007) Current and future management of psoriasis. Lancet. 370: 272–284.

Pittlekow M and Genebriera J. Psoriasis.Pharmacology and therapeutic principles to practice expert consult premium edition.pp 983-105

OECD Guideline for Testing Of Chemicals” 402, Adopted 24 Feb 1987

Vogel GH: “Drug discovery and evaluation: Pharmacological assays”, Springer Publishers, New York, Second edition, 2002:1323-1324.

Vijayalakshmi A, Ravichandiran V, Velraj M, Nirmala S, Jayakumari S. (2012) screening of flavonoid “quercetin” from the rhizome of Smilax china Linn for anti-psoriatic activity. Asian Pac J Trop Biomed. 2(4): 269-275.

Nagano K, Hori K, Nagane T, Sugarawa T, Oh-ishi J, Hayashi H, Watanabe N, Niitsu Y (1990) Effect of tumor necrosis factor in the mouse-tail model of psoriasis. Arch Dermatol Res. 282: 459–462

Danilenko DM. (2008) Preclinical models of psoriasis. Vet Pathol. 45: 563-575.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Copyright (c) 2020 Array

Downloads

Download data is not yet available.